Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
3.060
+0.030 (0.99%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Company Description
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States.
Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain.
The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery.
The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Nutriband Inc.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Gareth Sheridan |
Contact Details
Address: 121 South Orange Avenue, Suite 1500 Orlando, Florida 32801 United States | |
| Phone | 407 377 6695 |
| Website | nutriband.com |
Stock Details
| Ticker Symbol | NTRB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | February - January |
| Reporting Currency | USD |
| CIK Code | 0001676047 |
| CUSIP Number | 67092M208 |
| ISIN Number | US67092M2089 |
| Employer ID | 81-1118176 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Gareth Sheridan | Founder, Chief Executive Officer and Director |
| Serguei Melnik | Founder, President, Company Secretary and Executive Chairman |
| Gerald Goodman | Chief Financial Officer and Chief Accounting Officer |
| Dr. Alan Smith Ph.D. | Chief Operating Officer and President of 4P Therapeutics |
| Dr. Jeffrey Patrick Pharm.D. | Chief Scientific Officer |
| Michael Myer | President of Pocono Pharmaceutical |
| Tyler Overk | Head of Active Intelligence |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 22, 2026 | 8-K | Current Report |
| Jun 11, 2026 | 10-Q | Quarterly Report |
| May 18, 2026 | 10-K/A | [Amend] Annual report |
| Apr 29, 2026 | 10-K | Annual Report |
| Apr 7, 2026 | 8-K | Current Report |
| Feb 13, 2026 | 8-K | Current Report |
| Feb 13, 2026 | 424B3 | Prospectus |
| Feb 3, 2026 | 8-K | Current Report |
| Dec 30, 2025 | 8-K | Current Report |
| Dec 19, 2025 | DEF 14A | Other definitive proxy statements |